Milestone Scientific's FDA Cleared CompuFlo(R) Featured on the Doctor's Channel in Segment Entitled: Demise of the Traditional Syringe and Rise of the Smart Syringe System

LIVINGSTON, NJ -- (Marketwired) -- 06/23/17 -- Milestone Scientific Inc.'s (NYSE MKT: MLSS) Director of Clinical Affairs, Dr. Mark Hochman D.D.S, a world authority on computerized injection technology, was interviewed by the Doctor's Channel in a segment entitled "Demise of the Traditional Syringe and Rise of the Smart Syringe System." The Company's CompuFlo® Epidural Instrument featured in the segment received FDA clearance on June 12, 2017.

Dr. Hochman discussed topics related to the CompuFlo® Epidural Instrument and the technology behind it, called DPS Dynamic Pressure Sensing Technology™. This platform technology has the ability to measure pressure in real time and differentiate tissue by its density, in order to accurately identify and confirm the location of the epidural needle for precise targeting in the epidural space. Dr. Hochman also provided a visual demonstration of the ease of use and unique capabilities of the CompuFlo® Epidural Instrument.

The full interview is available at: http://www.thedoctorschannel.com/view/demise-of-the-traditional-syringe-and-rise-of-the-smart-syringe-system/

The Doctor's Channel boasts a universe of 450,000 subscribers and a video archive library of more than 6,000 health and medical videos. It offers free video CME, medical news, and physician education. It also features insights and opinions from experts in over 50 specialties, as well as community and lifestyle features that help doctors stay on top of the latest news, ideas, and information.

Dr. Mark Hochman, D.D.S., has served as Director of Clinical Affairs and Director of Research and Development for Milestone Scientific since 1999. He has a Doctorate of Dental Surgery with advanced training in multiple specialties in dentistry. He formally held a part-time faculty appointment as a clinical associate professor at NYU School of Dental Surgery for over ten years and he remains an active international lecturer on a variety of topics. He is recognized as a world authority on Advanced Drug Delivery Systems, having published numerous scientific articles in this area, and is credited for developing several new injection techniques using these innovative technologies. Dr. Hochman has been responsible for inventing and contributing to the development of much of the cutting-edge innovations from Milestone Scientific, he is the primary inventor for over 20+ patents and continues to advance the art and science of subcutaneous drug delivery systems.

About Milestone Scientific Inc.

Milestone Scientific Inc. (MLSS) is a leading medical research and development company that designs and patents innovative injection technologies. Milestone's computer-controlled systems are designed to make injections precise, efficient, and virtually painless. For more information please visit our website: www.milestonescientific.com.

Safe Harbor Statement

This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues, timing of regulatory approvals and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions, future business decisions and regulatory developments, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2016. The forward looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

David Waldman or Natalya Rudman
Crescendo Communications, LLC
Email: mlss@crescendo-ir.com
Tel: 212-671-1020

Source: Milestone Scientific, Inc.